首页> 美国卫生研究院文献>Clinical Pharmacology and Therapeutics >From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients
【2h】

From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients

机译:从适应性许可到适应性途径:提供灵活的生命周期方法为患者带来新药

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The concept of adaptive licensing (AL) has met with considerable interest. Yet some remain skeptical about its feasibility. Others argue that the focus and name of AL should be broadened. Against this background of ongoing debate, we examine the environmental changes that will likely make adaptive pathways the preferred approach in the future. The key drivers include: growing patient demand for timely access to promising therapies, emerging science leading to fragmentation of treatment populations, rising payer influence on product accessibility, and pressure on pharma/investors to ensure sustainability of drug development. We also discuss a number of environmental changes that will enable an adaptive paradigm. A life‐span approach to bringing innovation to patients is expected to help address the perceived access vs. evidence trade‐off, help de‐risk drug development, and lead to better outcomes for patients.
机译:自适应许可(AL)的概念引起了极大的兴趣。然而,一些人仍然对其可行性持怀疑态度。其他人则认为应扩大AL的重点和名称。在不断辩论的背景下,我们研究了环境变化,这些变化可能会使适应性途径成为未来的首选方法。关键驱动因素包括:患者对及时获得有前景的疗法的需求不断增长,新兴科学导致治疗人群的分散化,付款人对产品可及性的影响不断增加,以及对制药/投资人施加压力,以确保药物开发的可持续性。我们还将讨论许多环境变化,这些变化将使自适应范式成为可能。希望采用一种跨生命的方法来为患者带来创新,这将有助于解决人们认为的获取与证据权衡问题,有助于降低药物开发的风险,并为患者带来更好的结果。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号